Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

August 6, 2020

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 63 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Lashana, and I'll be serving as your conference operator for today. I'd like to welcome all of you to Cronos Group's Second Quarter 2020 Earnings Conference Call. This call is being recorded today. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, please go ahead.

Shayne Laidlaw

executive
#2

Thanks, Lashana, and I appreciate everyone being here today as we go over Cronos Group's financial and business results for the second quarter of 2020. With me on the call are Mike Gorenstein, our Chairman, President and CEO; Jerry Barbato, our CFO; and Xiuming Shum, our EVP of Legal and Regulatory Affairs. This morning Cronos Group put out a news release announcing our financial results, and those are filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before handing the call to Mike, I want to remind you that during this conference call our discussion will include forward-looking statements. Those statements rest on assumptions that carry risks and uncertainties, and actual results could therefore differ materially from what the forward-looking statements project, including because of the factors laid out in the cautionary statement and risk factors contained in the Company's earnings release and regulatory filings, including the Company's most recent annual report on Form 10-K/A and quarterly report on Form 10-Q, which qualify in their entirety any forward-looking statements made during this call. Also, during this call, certain financial measures may be discussed that are not recognized under the U.S.

Shayne Laidlaw

executive
#3

The SEC calls these non-GAAP measures, and they're rooted in Generally Accepted Accounting Principles. In our view, these non-GAAP figures help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You'll find a reconciliation of these non-GAAP measures to the nearest reported GAAP measures in our earnings press release furnished to the SEC, which sits in the press room section of our website, thecronosgroup.com. Measures used by other issuers may not be comparable to these non-GAAP measures. I'd also like to point out that we're holding today's call from our respective remote locations. Because of that, brief delays, cross talk, or minor technical issues may occur during this call. We thank you in advance for your patience and understanding. We'll now deliver prepared remarks, and after that we'll move to a question-and-answer session. With that, I'll hand things over to Mike Gorenstein, CEO of Cronos Group.

Mike Gorenstein

executive
#4

Thank you, Shayne, and good morning to all of you. To kick things off, there are two matters I want to discuss that are impacting people everywhere in the world right now. First, I'd like to talk about racism, and more specifically, how all of us at Cronos are focused on creating real change. As a leader in the cannabis sector, we have a duty to use our voice to move this industry ahead in a responsible way. That isn't possible unless we acknowledge the historical injustice that is specifically linked to cannabis prohibition and that still persists today. As we keep growing and enter new and evolving markets, we remain committed to backing meaningful, progressive reform and legislation on social justice in markets like the U.S. In our view, this work begins from the inside out. So we have set up a company to address how — pardon me, set up a committee to address how we as a company can have an impact in the communities where we operate, both through our time and through financial investment to fight racial injustice and inequity within our industry. We are fortunate to have a platform, resources and influence. And we will keep using it to do our part to combat racial injustice and to change society for the better.

Mike Gorenstein

executive
#5

Next, COVID-19 has affected markets, industries, and people around the world, which has brought about significant shifts in how we live and how we conduct business. We have also witnessed the deep impact that our products have on our consumers' daily lives. And we keep adjusting and watching over our distribution networks so that quality products reach the market during this period. Cronos Group was established with a mission of bettering people's lives through unlocking cannabis's full potential, and our Company has consistently led the way in offering safe access and top-quality products to patients and consumers. As you are aware, my focus and the Company's focus are on generating long-term shareholder value through the development of disruptive intellectual property and the building of iconic brands. I always advocate long-term thinking, particularly in the current economy and environment. Cronos is genuinely constructing a business for the future. Our value will stem from technological breakthroughs and branded sales that will assist in establishing relationships with our consumers. Turning to our operations in Israel. In June 2020, after the successful shipment of bulk dried flower from Canada to Israel, we began sales of PEACE NATURALS branded cannabis to the Israeli medical market. This marks an important milestone for Cronos, and we look forward to broadening our distribution and the PEACE NATURALS brand within the Israeli market.

Mike Gorenstein

executive
#6

Cronos Israel's team is likewise getting ready to launch additional SKUs in neighboring segments like oils and pre-rolls, and that will cement our leading position even further. Let me spend a moment going deeper on the Israeli market and on the way we have established ourselves as the leader in that country. Israel's population stands at slightly more than 9 million, and it holds one of the highest rates of cannabis consumption anywhere in the world. In contrast with North American cannabis markets, the illicit market in Israel is far less competitive, because of the country's strict border controls and security infrastructure. Several measures have been taken by the Israeli government to streamline and speed up the process through which patients access medical cannabis. Back in 2016, a medical cannabis information booklet and guide was published by the Israeli Ministry of Health, and it contains the methodology doctors are meant to follow when prescribing cannabis. The purpose is to guide and help in tailoring treatments using medical cannabis. Numerous doctors within Israeli healthcare systems have completed training and certification in this clinical methodology, which allows them to deliver treatment and issue patients licenses to possess and use medical cannabis. Personal medical cannabis permits and prescriptions are presently granted to patients by the Israeli Medical Cannabis Agency for the treatment of various medical conditions.

Mike Gorenstein

executive
#7

And in contrast to the Canadian medical cannabis program, patients get their prescriptions filled straight through pharmacies. We expect the number of medical patients in Israel to rise quickly, which represents a great chance for our business to expand in this market. The fast expansion of the Israeli medical market brings to mind the early days of Canada’s medical market, when demand exceeded supply and the stigma attached to the product was fading fast. Beyond Israel’s medical market, we are encouraged by the progress on further legalization of the potential adult-use market, which offers more legal access to cannabis in Israel. Right now the government is reviewing two bills, and they are moving through parliament faster than many had expected. As a reminder, Cronos Group consolidates its results and captures 90% of the economics via our equity interest across the Cronos Israel entity. With our manufacturing footprint, established local team, strong brand and product portfolio, we are very well-positioned to succeed in the market. Kibbutz Gan Shmuel is one of the largest and most sophisticated kibbutz teams in Israel, producing and exporting a variety of products to 35 countries throughout Europe and Asia. For our Cronos Israel facility, we work closely with our partners at Kibbutz Gan Shmuel and are able to leverage not only their agricultural expertise, but also their skilled labor pool, with about 80 employees currently working on site and extensive infrastructure, including warehousing, utilities, and much more.

Mike Gorenstein

executive
#8

I'm happy to report that we're now at full production and have completed a successful harvest. Beyond Cronos Israel's own direct operations, we've made a deeper commitment to the region and maintain a robust presence when it comes to R&D and analytical sciences. We have two partnerships in place with a leading cannabis researcher, Dr. Dedi Meiri — one through the skincare repair research we're conducting at Technion, and the other through the analytical testing lab located on Cronos Israel's campus, which is called Cannasoul. As part of our agreement, Cannasoul is building a commercial cannabis analytical testing business at the Cronos Israel site. We've also established our own research hub, Cronos Device Labs, which has roughly 30 employees and concentrates on areas ranging from grasping how various cannabinoids behave to designing next-generation devices for cannabis products. Now shifting to the Canadian market. During the second quarter, we kept supplying the adult-use market, collaborating with provinces and private retailers to satisfy demand throughout this period. With COVID-19 still affecting global markets and worldwide supply chains, we've observed a rise in sales fueled by consumer demand along with the expansion of retail outlets in key provinces. Notwithstanding the strength we've witnessed and the ongoing store openings in certain provinces, we're staying cautious, aware that the shock to the economy might potentially deal negative blows to our industry.

Mike Gorenstein

executive
#9

In Canada, what we're seeing right now is that the majority of retailers are open at reduced capacity and following social distancing rules. A number of provincial purchasers are still putting health and safety protocols in place and cutting staff at on-site operations, and that includes restricted delivery windows, which have caused logistical headaches and led to fewer purchase orders being filled. Beyond the quarantine steps and travel limits, retailers are dealing with this slowdown and disruption, and those factors could affect how easily consumers can get our products outside of online channels. Forecasting consumer demand and sales velocity is made uncertain because these restrictions keep shifting and evolving. Even with the landscape changing through the second quarter, retail store authorizations kept being granted by the Alcohol and Gaming Commission of Ontario, with the goal of widening availability of the legal cannabis supply. As of July, more than 100 stores had been authorized to open, and Ontario appears committed to its plan of increasing store count month by month through 2020, with a long runway for growth thanks to demand for new retail licenses. In the Canadian 2.0 market, our adult-use brands Spinach and COVE, along with PEACE NATURALS, our direct-to-consumer medicinal cannabis brand, kept growing their distribution across the country within their respective channels.

Mike Gorenstein

executive
#10

Our commitment to quality is something we take real pride in — it sits at the core of all our work. As we keep gathering deeper consumer insights about the Canadian market, we're eager to bring out new and differentiated products as time goes on. We recognize that adult-use consumers and medical patients in Canada are seeking value right now, and a number of our peers have opted for a deep discount strategy as their way of delivering that perceived value to consumers and competing with the illicit market. Here at Cronos, we hold that the true essence of value comes down to a tradeoff between what benefits the consumer sees in the product and the price he or she pays for it. We take pride in the quality of the product we bring to market. For example, our vaporizer devices are designed to deliver premium extracts to consumers, with precise cannabinoid concentration levels and terpene profiles for a consistent experience. Those premium cannabis extracts are produced through CO2 extraction processes, and every product has a unique and aromatic blend that uses all-natural terpene-rich flavors. Every one of our batteries and cartridges undergoes rigorous testing before sale, and positive feedback on these innovative new products keeps coming in.

Mike Gorenstein

executive
#11

We think the value we offer consumers right now, in terms of both benefits and pricing, is quite strong. As the industry keeps evolving, we'll keep examining how to deliver additional value to consumers on a regular basis, whether that comes through benefits or through price. Turning to the U.S., I'd like to begin by welcoming Summer Frein to her new position as General Manager of our U.S. segment. Summer was named last month to lead our U.S. hemp-derived CBD business, with responsibility for sales, marketing and operations. She formally came on board at Cronos in January of this year, though she has been with the team since 2018 through her role at Altria. During her time at Altria, Summer headed the strategy and business development teams' due diligence in the cannabis space, work that resulted in the strategic investment from Altria. She has overseen our U.S. sales efforts, which includes managing brand and retail partnerships for Lord Jones. Summer is a proven, results oriented leader who brings 14 years of regulated consumer packaged goods experience. We have confidence in our U.S. brands and in our strategic direction under Summer's leadership. We see many opportunities ahead, from introducing new product formats under Lord Jones to launching new brands and targeting different retail channels and consumers.

Mike Gorenstein

executive
#12

During the previous quarter, responding to what the market told us and as one piece of our ongoing push to deliver genuine value to consumers, our Lord Jones brand introduced a new size option for our flagship item, the Lord Jones CBD Body Lotion. Offered now in a bigger 100 ml bottle, this well-liked body lotion gives you double the amount while carrying the identical price tag as our initial 50 ml version. Alongside that launch, we cut the price on our original 50 ml size by 30%. We believe this fresh pricing approach creates an excellent entry point for drawing trial shoppers into the brand and turning them into repeat buyers. The backing we received from our consumers over this quarter has themselves and we're eager to be delivering these new format sizes and products to devoted Lord Jones customers. We'd be careless if we didn't note the work underway with Ginkgo and our joint venture Natuera. After successful fermentation of CBG at R&D scale at Cronos Fermentation, we have kept refining the process for downstream processing and scale-up procedures, and we are highly satisfied with results so far. Given the progress achieved, we stay on track to make fermented cannabinoids at commercial scale in September 2021.

Mike Gorenstein

executive
#13

And over in Colombia, our joint venture Natuera pulled off three more test shipments of hemp-derived CBD extracts to the U.S. between May and July of this year, for business development and R&D purposes. Now, this doesn't mean revenue has started for that business, but the learnings are valuable and they position us well going forward. In these unprecedented times, it's really encouraging to see progress against our strategy across our global footprint. The current environment isn't easy for any industry, especially not one at a nascent stage of development. Still, I'm very proud of our employees and everything we've accomplished during this period. From our production and manufacturing facilities to our ongoing R&D efforts, we're creating and launching new products and brands in different markets around the globe. And we remain committed to bringing high-quality brands and products to our consumers. There are a few silver linings in this environment. First, with our strong balance sheet and competitors in the industry facing decreased access to capital, we continue to feel extremely well-positioned to be opportunistic in how we create value for shareholders. Second, we believe that as attention turns toward economic recovery, accelerating cannabis legalization is a great solution to help create much needed jobs and tax revenue.

Mike Gorenstein

executive
#14

The future isn't something we can ever fully predict, yet our optimism holds, and we stand prepared to grab chances whenever they appear. On that note, I'll hand things over to Jerry, who will walk through the financial results for this quarter along with what we've been doing on remediation.

Jerry Barbato

executive
#15

Thanks, Mike, and good morning to everyone. Now I'll move on to our financial results. For the second quarter of 2020, the Company reported consolidated net revenue of $9.9 million, which represents a 29% increase compared with the prior year period. The year-over-year revenue growth came mainly from continued growth in cannabis products in the Canadian adult-use market and from including Redwood's financial results — our U.S. hemp-derived CBD business that was acquired in September of last year. Revenue was partly offset by non-recurring wholesale revenue in the Canadian market during the second quarter of 2019. Consolidated gross profit for the second quarter of 2020 was negative $3 million, a decline of $7 million from the second quarter of 2019. The decrease versus prior year was driven primarily by a $3.1 million inventory write-down on dried cannabis and cannabis extracts within the Rest of World segment, caused by cannabis price compression in the Canadian market, as well as by an increase in cost of sales, driven by a higher volume of adult-use sales and the lack of wholesale revenue. If we were to exclude the inventory write-down of $3.1 million, gross profit in the second quarter of 2020 would have been $0.1 million, representing a gross margin of 1%.

Jerry Barbato

executive
#16

We expect inventory write-downs will persist near term because of pricing pressure in the market. For the second quarter of 2020, the reported operating loss came in at $34.8 million, which is a decline of $18 million compared with the second quarter of 2019. That loss stemmed from a mix of factors: lower gross profit; general and administrative expenses reflecting more headcount; sales and marketing costs tied to building out new and existing brands and product lines; and R&D expenses, largely from higher spending on research at the Cronos Device Labs Research and Development center and from upscaling activity at Cronos Fermentation. Also, inside G&A, we incurred $3.5 million of expenses, driven by review costs and costs tied to the Company’s responses to information requests from various regulatory authorities concerning our previously disclosed restatement of our 2019 interim financial statements. Our consolidated adjusted operating loss for the second quarter of 2020, which excludes the one-time review costs, was $31.3 million. Now to our reporting segments. In the Rest of World segment, net revenue for the second quarter of 2020 was $7.7 million, up 1% from the prior year period. The year-over-year revenue growth was driven mainly by greater distribution of cannabis products in the Canadian market, including the launch of cannabis vaporizers in both the adult-use and direct-to-consumer categories, partly offset by nonrecurring wholesale revenue in the Canadian market in the second quarter of 2019.

Jerry Barbato

executive
#17

For the Rest of World segment, gross profit came in at negative $3.5 million, which is a $7.6 million drop compared with the second quarter of 2019. That year-over-year decrease was mainly the result of a $3.1 million inventory write-down on dried cannabis and cannabis extracts, driven largely by pricing pressure in the Canadian market along with the higher volume of adult-use sales and a lack of wholesale revenue. Excluding that $3.1 million inventory write-down, gross profit for the second quarter would have been negative $0.5 million, which works out to a negative 6% gross margin. As we work toward building an efficient global supply chain for 2020 and beyond, we expect gross margins to keep fluctuating. That reflects the current underutilization of certain manufacturing facilities that are being repurposed, as well as the work underway to streamline our third-party biomass supply chain. We expect these operational pressures to ease as our manufacturing and purchasing teams keep making progress in these areas. Now turning to our Canadian cannabis vaporizers, as we have discussed before, we made the strategic decision at launch to use contract manufacturers so we could increase speed to market at the onset of Cannabis 2.0 legalization. In addition, we believe contract manufacturing lets us be more flexible and responsive to marketplace trends while also aligning with our asset light model.

Jerry Barbato

executive
#18

We keep collaborating with contract manufacturers in order to lower expenses, and at the same time we go on delivering quality products to our consumers. The reported operating loss for the Rest of World segment in the second quarter of 2020 came to $22.1 million, which represents a $5.4 million decline from the second quarter of 2019. That loss was mainly driven by a decrease in gross profit and by higher R&D costs tied to our spending on research at the Cronos Device Labs R&D scale center, along with upscaling activities at Cronos Fermentation. Before I get into the operating results of the U.S. business, let me discuss the impairments we took this quarter in that segment. The Company recorded $35 million of impairment charges on its reporting unit and $5 million of impairment charges on the Lord Jones brand. Because of the ongoing developments of the COVID-19 pandemic, retail store closures have lasted longer than expected, and revenue growth has been slower than anticipated. With growth slower, the Company's operating results in the U.S. segment have been negatively affected by the global pandemic, and the timeline for society getting back to normal is uncertain. Based on the valuations, the carrying value exceeded the fair value, which resulted in an impairment on both the reporting unit and the Lord Jones brand.

Jerry Barbato

executive
#19

Now on the U.S. business: net revenue came in at $2.2 million for the second quarter of 2020. The U.S. segment's gross profit was $0.6 million, a gross margin of 27%. In our view, the compression in U.S. gross margins this quarter was transitory in nature — it came from premiums we paid essential employees during the COVID-19 pandemic, plus higher discounts and promotions in the direct-to-consumer channel aimed at growing online sales to help offset the negative effects of retail channel customer closures due to COVID-19. The U.S. segment posted an operating loss of $5.6 million for the second quarter of 2020. That loss was mainly the result of lower gross profit. Sales and marketing costs were tied to developing and launching new U.S. hemp-derived CBD products under the Lord Jones brand, new brand development, and added headcount supporting growth initiatives across a variety of functions. On an overall basis, Cronos Group reported lower net income than the prior year, chiefly because of non-cash impairment charges and the change in fair value of the financial derivative liability tied to Altria's investment, which the 10-Q describes in more detail.

Jerry Barbato

executive
#20

During Q2, we booked a non-cash loss of $35.9 million tied to how the fair value of those financial derivative liabilities moved. Cronos still anticipates that reported earnings could swing significantly, mainly because of quarterly fair value adjustments driven by movements in Cronos Group’s share price. Moving to the balance sheet: we closed the quarter with roughly $1.3 billion in cash and short-term investments, essentially unchanged versus the first quarter of 2020. Capex during the quarter came to $8.6 million. That outlay covers investments in Cronos Fermentation, the PEACE NATURALS campus, our Israeli facility, and our new ERP system, which I’ll discuss in more detail shortly. We stay committed to putting capital to work in a disciplined way, and only in ways consistent with our strategic priorities. I’d now like to update you on our remediation work regarding the material weaknesses we disclosed in our fourth quarter of 2019 filings. As a company, we are committed to adopting best practices for financial reporting. Our management, with oversight from the audit committee, keeps working diligently to phase in our plan, and we have achieved substantial progress in the implementation process to-date.

Jerry Barbato

executive
#21

All the controls we outlined last quarter to address the material weaknesses are now in place, and we've started rigorous internal testing. Our independent auditor is currently testing certain controls and will move on to the remaining controls over the course of 2020. Then, to make our organization more efficient, we successfully rolled out an ERP system across our Canadian businesses, which went live in July. We've also begun work to extend the reach of that ERP system to our U.S. business, with a launch expected in the first half of 2021. That new ERP system will be a meaningful component of internal control over financial reporting and will let us lessen our reliance on manual controls and achieve efficiencies throughout our supply chain and operations. I remain encouraged by what our teams are doing globally, both in our wholly-owned business and with our JV partners. With that, I'll hand it over to Mike for closing remarks before Q&A.

Mike Gorenstein

executive
#22

Thank you, Jerry. Even with unheard-of changes in the world economy and in how we live, Cronos has stayed focused on delivering against our priorities, and we are well-positioned to weather the storm. We continually evaluate what our consumers need as it shifts. Whether our consumers are seeking positivity, self care or wellness, we remain committed to providing quality products with the level of consistency and quality that consumers have come to expect from our brands. Our strategy, which is built on multiple growth engines, is as vital as ever. Our growing diversified portfolio of brands, which participate across geographies, channels and categories, provide us with many ways to fuel our global business. And our asset light model will continue to play a crucial role as we continue to scale our business. Cronos has always been a company of people that thrive in new markets, embrace change, and welcome hard problems. And by staying flexible, we are positioned to opportunistically create value as the landscape continues to shift. With that, let’s now open the line for questions.

Operator

operator
#23

Tamy Chen from BMO Capital Markets has our first question.

Tamy Chen

analyst
#24

Hello, and thanks. Good morning to all. My first question, Mike, is this: I believe you mentioned before that regarding your wider strategy, one element involves sort of allowing or waiting for the industry to sort itself out — both in Canada and even in the U.S. — before you make bigger moves. So I just want to get a sense of where you stand on that. I mean, has the industry begun to develop or mature somewhat more, such that you're now considering potentially making some bigger moves in the business?

Mike Gorenstein

executive
#25

Okay, so if we take Canada as an example — and I'll address Canada and the U.S. one at a time. What we're really after, I think, is identifying where our brands are distinctive offerings and how they connect with consumers. Before we'd consider any bigger acquisitions, we'd want to see market share that holds steady and clear separation across various consumer segments. That hasn't really materialized so far. And the swings in market share, I'd say, are something that keeps showing up quarter after quarter. From an ROIC standpoint, what matters a great deal to us is confidence that we can obtain something meeting consumer needs that we can extend across borders and genuinely scale while building a moat with consumers. And with the product and brand launches still at an early stage, it's difficult for us to identify anything where an acquisition would serve us better than simply continuing to build things ourselves, at least right now. As for the U.S., I'd describe it as more a matter of regulation at this point. I think you are seeing somewhat more of an uptick in how consumers relate to brands.

Mike Gorenstein

executive
#26

But keeping an eye on how the regulatory landscape evolves and staying proactive about it — and I think since many of the various COVID-related developments probably speed up our timeline for when legalization arrives, that likely moves us nearer to the point where we'd make one or more moves in the U.S. Still, because of the restrictions, this isn't something that's going to happen right away.

Tamy Chen

analyst
#27

My next question concerns Israel. From what you said, I see several of your Canadian rivals now bringing products into that country's medical sector as well. In fact, it appears to have shifted toward being a net importer, whereas I believe earlier ties had it as a net exporter. Given the production hub you have located there, I'm curious whether this changes your approach in Israel. Also, when you consider the chance there—the market's size, and clearly the population is below Canada's—can you quantify how many patients exist at present, and what the opportunity might amount to in the future?

Mike Gorenstein

executive
#28

So, Israel strikes me as a really exciting market. And although our initial idea was to use it as an export hub, the fast expansion of the medical market has surprised us in a good way, and it keeps doing so. The population there is smaller than Canada's. So from a top-line standpoint, the addressable market size probably won't match. But I'll point out that you simply don't face the same kind of competition from the illicit market. That's an interesting dynamic we really haven't seen in other markets. On cost and price competitiveness, I think it's hard to see Canadian exports supplying the Israeli market over the long term. For us, it's about using our Canadian production to supplement what we currently have domestically there. I think the conditions and environment in Israel simply make producing there more advantageous. So I expect we'll keep seeing rapid growth. We — I think it's too early to give any specific numbers. But I do use the analogy of Canada a few years ago, where, if you go back, we were seeing a lot of growth in the medical market and there was a shortage, but now that we've been through the first readings in the Israeli parliament on a legalized — a more full legalization bill, I think we view our domestic footprint as something that will be essential and give us a big advantage when legalization comes.

Mike Gorenstein

executive
#29

And once more, a smaller group of people, but — and although it’s still early in structural terms, having the ability to move straight from a producer to a store with no wholesalers involved ought to make scaling simpler, and from a margin standpoint, we’d anticipate it being more appealing. So, I’d say the medical market is one piece of it, and getting ready for full legalization is another thing we’re highly focused on.

Operator

operator
#30

The next question is from Rahul Sarugaser at Raymond James.

Rahul Sarugaser

analyst
#31

Morning, Mike and Jerry. Appreciate you both taking my question. As you know, we put a lot of emphasis on the biology <<inaudible>> program. So, Jerry, you mentioned some rising costs tied to experimentation. It would be helpful to hear an update on where those costs are landing and how the scale-up is progressing. Mike, does the timeline still point to September of next year, or does that still hold?

Mike Gorenstein

executive
#32

Absolutely, and thanks — good morning, everyone. So, I’d say the scale-up costs are there, and there’s some significant CapEx across various infrastructure pieces: making sure commercial fermentation infrastructure is ready, having the different security packages in place — all of that is planned CapEx. But some work was required to take the facility from the time it was used, and still is for pharmaceuticals, under Apotex and convert it into something that sits under C-45, and that’s where a portion of the costs comes from. And we’ve been running a number of runs, and we keep raising production. So, there are costs associated with that. That said, I think it’s been going well, and the rising cost is a positive, because it shows we’re continuing to ramp up and figure out downstream processing. So, there will be costs as we build out the downstream processing trains so we can efficiently take the fermented cannabinoids and make sure they’re just fungible in our supply chain. So that in September, we’re in a position where we can take cannabinoid from fermentation or take cannabinoids from extraction, and they seamlessly fit into the products we have on the market today and in the products that we have in our development pipeline.

Rahul Sarugaser

analyst
#33

And I have one quick follow-up, if I may. Activity is clearly expanding, and with the regulatory picture beginning to clarify — especially where CBD is concerned — how might you potentially grow that program or extend it into the U.S.?

Mike Gorenstein

executive
#34

Absolutely, and this is definitely something we're focused on. I'd say it isn't limited to CBD—there are additional cannabinoids we're also concentrating on. Much like Canada, we intend to broaden our offerings. If you look at how we've set things up in the Canadian market, much of what we do naturally centers on the Canadian consumer, but we're also aiming to gain insights that let us smoothly carry those products and processes into the U.S. So the products we expect will succeed in Canada, I believe, only strengthen our position for the moment we finally do enter the U.S. market. There are particular things permitted in the U.S. market and particular things permitted in the Canadian market, and once we can merge those, I think the resulting combination is far more potent. The Canadian market's benefit, then, is the ability to operate specifically on the more tightly regulated cannabinoid side. With THC and THCV, being able to collaborate with universities, being able to leverage the kind of infrastructure we possess and conduct that research is extremely, extremely valuable. Naturally, with the U.S. being the biggest consumer market, we continue to carry out our consumer research there.

Mike Gorenstein

executive
#35

and concentrating on building products that will ultimately satisfy what consumers in the U.S. market need.

Operator

operator
#36

Andrew Carter from Stifel has the next question.

Andrew Carter

analyst
#37

My question concerns the <<inaudible>> business, particularly the Canadian adult-use segment. For 2 consecutive quarters now, gross margin has really been weakening. And I realize you cited lower pricing. So, I suppose, a few questions. First, at what point do you expect gross margins in this business to stabilize? And then, since you do use third parties for flower costs, are you underwater on costs? Are you seeing any easing in flower costs at all?

Jerry Barbato

executive
#38

So we won’t be giving guidance on margins from here on out, but as we mentioned during our prepared remarks, margins in the Rest of World segment are going to keep fluctuating over the coming period — due to both market dynamics and our strategy, which we think is positioning us for long-term success, and we feel confident about our asset light model. That said, with this asset light model, we are facing some margin pressure at present. As the cost of third-party flower declines over time, our margins should strengthen. Then, broadly in the market, we’re observing ongoing pricing pressure throughout the Canadian market, where producers are cutting their prices and offering larger format size offerings. And then, as Mike mentioned in his remarks, we are ramping up Cronos Israel’s business and have only just started sales in that medical market, which is going to have some effects on our margins.

Andrew Carter

analyst
#39

Taking a step back and considering the Lord Jones business, it has clearly been hit quite hard—but particularly with the impairment you took, which implies you reviewed the business. What are your expectations for that business, if you could share any long-term targets for it, and will it grow in the second half, or is 2020 simply going to be a difficult year given all the challenges from COVID-19?

Jerry Barbato

executive
#40

We have faith in the team and in the business plans going forward. Still, outside factors are hard to forecast. That unpredictability is what prompted us to project this business out. And I can tell you that as 2020 began, we felt very enthusiastic about the potential for substantial growth in the U.S. business. However, the COVID-19 pandemic has hit many of our customers hard, with some facing temporary store closures and others shutting permanently, and frankly that has hurt sales and demand in the segment. So at this moment, forecasting what the remainder of 2020 will bring is very difficult for us. Because while stores reopen in certain states and localities, they are being forced to close again, and what you truly cannot determine is how the consumer will be affected in the near term. Simply because a store might reopen, you will not see the same foot traffic coming through, nor the same interactions, nor the same count of people permitted inside stores.

Operator

operator
#41

The following question is from Seth Rubin at CIBC.

Seth Rubin

analyst
#42

Hi there. Seth here, filling in for John Zamparo. Appreciate you taking my questions. So, I suppose, keeping the focus on Lord Jones, are there any indications that you can make up for the brick-and-mortar decline via online channels — whether that's direct-to-consumer or online retailers? And then, I guess, we'd welcome any update on Lord Jones as far as the CBD strategy overall is concerned.

Mike Gorenstein

executive
#43

At first glance, the fact that our U.S. business was flat quarter-over-quarter might look somewhat disappointing. COVID clearly hit our brick and mortar sales hard. Still, I would say we did fairly well in the second quarter, given that we had very little sales to our retail partners and were focusing on our direct-to-consumer. Now, along with that, we ran a lot of price promotions and discounts to drive those sales. But quarter-over-quarter, despite having such little revenue to those retail partners, and then as we look forward, I mean, we feel confident in the plans that business has to correct the trajectory of that business, and are very excited to see what Summer will do to lead the business forward.

Seth Rubin

analyst
#44

And if I could squeeze in one quick follow-up there, specifically about how you plan to allocate capital going forward — is there any chance we might see some notable CapEx projects coming down the pipeline?

Mike Gorenstein

executive
#45

We constantly look at opportunities, though given the brand portfolio we hold, at present we feel fairly comfortable with our position from an infrastructure standpoint. Aside from any acquisitions or additional launches where we might wish to offset margin pressure through CapEx, we feel fairly comfortable with where things stand today. So there isn’t much to anticipate on that front.

Operator

operator
#46

The upcoming question is from Vivien Azer at Cowen.

Vivien Azer

analyst
#47

I'd like to ask a follow-up question about Lord Jones too, please. There were definitely several moving parts during the quarter, especially as we attempt to triangulate toward normalized gross margins. So on one hand, you've got the price cut on your core offering, along with heavier promotion. But my thinking is that given the depletion you're seeing in the commodity market, there ought to be some sort of offset. So can you give us any color — if you try to normalize for all of those puts and takes, distribution, price adjustments, and commodity deflation — on what the gross profit profile would have looked like?

Jerry Barbato

executive
#48

Thanks, Vivian. So yes, U.S. margins took a hit from two things—revenue and cost of goods sold during the quarter—both because of COVID and how we responded to the pandemic. Starting with the net revenue side, we offered more discounts and promotions to consumers in the online channel. We ran a lot of those 30% discounts. Then on the cost side, we gave our essential employees premium pay, and that pushed our costs higher. So both of those factors weighed on margins in the quarter. I think it's difficult to forecast when margins will return to some kind of normal, given the COVID pandemic and retail stores reopening. But you're absolutely right. I mean, some of our costs are going to come down. So the question is whether that gets offset by the premium pay. And on the revenue side, what happens with the retail environment?

Vivien Azer

analyst
#49

Got it. Perhaps I could just ask a quick follow-up that's a bit more specific. Could you give some context on what you're observing regarding price deflation on the input side for the Lord Jones product?

Jerry Barbato

executive
#50

Yes. I think prices have definitely dropped quickly, but it does take a while for that to actually show up in the margins you're seeing. If you consider, from an accounting standpoint, when new product — or sorry, new input would actually line up with the product we're selling, we do see it coming down. We think it might even fall further. But it takes time for us to work through the current CBD supply we have on hand.

Operator

operator
#51

Michael Lavery from Piper Sandler has the next question.

Michael Lavery

analyst
#52

With PEACE+ seemingly ready to roll out in Arizona, California, Illinois, and Pennsylvania, could you share some sense of how soon that might happen, how wide the launch could be, and what makes those states the ones chosen?

Mike Gorenstein

executive
#53

With PEACE+, we’re still watching how the broader picture develops—regulations included, and simply what’s going on in retail—before we push into a bigger rollout. And when it comes to where we’re putting our attention in the second half of this year, it’s really on other brands: Lord Jones, plus a skincare label that’s more mainstream—that’s where our focus would sit. That said, since everything for PEACE+ is now in place, we’ll stay opportunistic on timing, so that once the right moment and the right opportunity appear, we’ll go ahead with it.

Michael Lavery

analyst
#54

So there isn't a fixed timetable you can give us?

Mike Gorenstein

executive
#55

No fixed timeline exists for this. My sense is that it comes down more to timing — we first want to make sure our brand reaches the market, and then have PEACE+ ready to go. Once that's done, we'll begin rolling it out.

Michael Lavery

analyst
#56

And just as a quick follow-up — I realize we've already gone over Lord Jones quite thoroughly. Still, I'd like to get a sense of what drove the write-down, in the sense that — normally, in a case like that, if the pressure were viewed as transitory, a write-down wouldn't be necessary. If there's something beyond the COVID-19 pressure that you're referring to, has your view of the market shifted, or is this more of a conservatism approach, or just how did you think about that?

Mike Gorenstein

executive
#57

We performed an in-depth review. And yes, certain pressures exist that should be temporary. And we have fallen short of what the original model projected. And the thing we cannot know, and that is hard for us to forecast, is this: how long will COVID persist? And after that, how long will its effect on consumer behavior persist? So yes, I would say we did take a cautious approach. I simply believe that given the COVID pandemic and the sizable share of this company’s customers who have dealt with closures and strain on their businesses, when we ran the analysis, the impairment was the sensible course of action.

Operator

operator
#58

Up next, we have a question from Bill Kirk at MKM Partners. Once more, the question comes from Bill Kirk of MKM Partners. That line isn't responding. Our next question is from Matt Bottomley at Canaccord Genuity.

Matt Bottomley

analyst
#59

Mike, I wanted to see if you could offer a bit more color on your thinking around brand building. More specifically, what's going on in Canada, where retail sales clearly keep expanding at a fairly healthy pace, while at the same time there are some dynamics around inventory becoming less abundant across this sector and around how some of your peers are setting prices. So given that many of your comparable peers with similar market caps — some of the bigger names — have greater penetration, what's your rough mix, or tradeoff, between running, say, a more restrained OpEx burn versus what those peers are doing, versus building brands and even simply moving products today at breakeven just to get product out there? Given that you really can't advertise, and there isn't much differentiation, when you walk into these stores, maybe that's not much of an issue. But I'm just curious how you see that playing out over the long term as Cronos looks to build its own brands in the domestic market?

Mike Gorenstein

executive
#60

Absolutely, and thanks — good morning. That’s a really good question. First, I’d say that when we think about building brands, our thinking is on a global scale. And while it’s true you can’t run broad advertising and you may face tight restrictions, there are still methods available for advertising. That said, brand building isn’t only about how your packaging looks or whether you can put up billboards. In terms of our approach to creating value, I’ll draw an analogy and look at, let’s say, the tobacco industry more than 100 years ago. If you go back and consider that early market, what you’d see is probably quite comparable to where the Canadian flower market stands today, with industry participants competing to work out how to sell loose leaf tobacco. Yet the greatest value creation in the end didn’t come from whoever could outsell another player in tobacco leaf. It came from researching what consumers need and being able to develop a breakthrough consumer product, such as cigarettes. And we think Cronos has a similar path to value creation. So it means keeping our focus on what that breakthrough product is, being able to bring it to market, and not just being able to bring that product to market in Canada but being able to then take that product and also launch it in Israel and the U.S.

Mike Gorenstein

executive
#61

And as full legalization arrives in other markets too. So I think it matters that we've got product available in the market, that we possess the sales and manufacturing infrastructure allowing us to keep those relationships going, so we're set when differentiated products are ready to launch. And I think the right pieces are in place given the work done since Todd came aboard as Chief Innovation Officer, and how we bring differentiation into products through rare cannabinoids and various form factors. But my view is that building a brand essentially on flower, which is commoditized, and with Canada's restrictions and regulations, is going to be hard. Still, there's opportunity through product differentiation. And that's truly what we must be able to accomplish. Until we offer a product that's different, I think consumers will keep switching among brands, and we need to give the consumer something better.

Matt Bottomley

analyst
#62

Turning to the other side of that, though. Your balance sheet is among the strongest in the sector. With the current operating burn you have, do you feel comfortable funding those interim losses while we pursue longer-term brand building at more differentiated opportunities, or is there a four-to-six-month window — or a four-to-six-month quarter beyond wherever you'd obviously like to get to breakeven or above?

Mike Gorenstein

executive
#63

When you consider how we're structured and the end markets we target compared with our current position, our real emphasis is on longer-term return on invested capital rather than the timing of becoming cash flow positive. And I believe our balance sheet is structured in a way that lets us absorb that. Still, we are genuinely investing so we can develop breakthrough products and bring them to market, since that's where we believe the greatest value lies. None of that means we've stopped paying attention to costs, but what matters to us is ensuring we can cut and eliminate expenses that aren't delivering a solid return on the investments we make. Even so, anything we spot opportunistically — or that aligns with our strategic plan and allows us to invest — we will keep pursuing.

Operator

operator
#64

The last question is from Graeme Kreindler at Eight Capital.

Graeme Kreindler

analyst
#65

I was hoping you could give me a little more detail on how the Rest of World revenue shifted across the different segments from one quarter to the next. In the quarter, I noticed flower revenues were more than twice what they had been, whereas extracts declined. So I was wondering if that gain in flower came from exports into international markets, and I wanted more specifics on the extract side, particularly with vapes having launched. I'd just like additional detail on what's driving that variance and what falls within that broader category.

Jerry Barbato

executive
#66

So I think what you're looking at — at least when you compare Q2 of 2020 with Q2 of 2019 — is that our revenue is fairly flat, but in the second quarter we sold every one of our products in the Canadian marketplace, whether through the rec channel or the medical channel, while back in Q2 of 2019 we had a big wholesale shipment. And I think you really can't compare extracts with flower — whether that's pre-rolls, or even tincture oil and vapes — on a quarter-over-quarter basis. There are always going to be fluctuations in the mix, in my view.

Mike Gorenstein

executive
#67

To build on that, I want to flag one distinction when you’re measuring us against peers: since we operate our own distribution through the Israeli entity, exporting from Canada into Israel doesn’t register as revenue at the point of export. Revenue is recognized only once the branded product is actually sold through in Israel. So you get a bit of a lag, and I’d suggest thinking about Israel less as an export market and more as an operating company, with revenue showing up there much the way Canadian revenue does. Whether the product is imported or made in Canada really comes down to a supply chain matter.

Graeme Kreindler

analyst
#68

And then I have one quick follow-up question. I appreciate the earlier commentary about the USA segment and how its gross margin has fluctuated. Now, looking at the adjusted operating loss on a quarter-over-quarter basis, it actually improved by about 15%. So I was hoping to get a bit more detail on how revenues were flat and gross margin declined, yet profit figures actually went up. I'm just wondering what's driving that.

Jerry Barbato

executive
#69

Yeah. I'd say most of that comes down to when our spending happens. We spent a lot in Q1 and less in Q2. So that's really the explanation. Looking at that business quarter to quarter is tough, I think.

Operator

operator
#70

That wraps up the question-and-answer portion of today's call. We appreciate everyone taking part. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.